Revelation Biosciences, Inc.
REVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $4 | $5 | $7 |
| G&A Expenses | $4 | $5 | $5 | $5 |
| SG&A Expenses | $4 | $5 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $9 | $11 | $12 |
| Operating Income | -$8 | -$9 | -$11 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7 | $9 | $0 | -$0 |
| Pre-Tax Income | -$15 | -$0 | -$11 | -$12 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$0 | -$11 | -$12 |
| % Margin | – | – | – | – |
| EPS | -87.68 | -8.41 | -9,643.37 | -20,400 |
| % Growth | -942.6% | 99.9% | 52.7% | – |
| EPS Diluted | -87.68 | -8.41 | -9,643.37 | -20,400 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$9 | -$11 | -$12 |
| % Margin | – | – | – | – |